Published: February 25, 2013
Actavis' Generic Suboxone® Receives FDA Approval
PARSIPPANY, N.J., Feb. 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone(®).
Actavis intends to begin shipping the product immediately. Suboxone(®) is indicated for maintenance treatment of opioid dependence.
For the 12 months ending December 31, 2012, Suboxone(®) tablets had total U.S. sales of approximately $625 million, according to IMS Health data.
To read the complete release at NewsBlaze,
Actavis' Generic Suboxone® Receives FDA Approval,
Related PRNewswire Releases News
Brandon Blue and the rest of the team of mortgage professionals at Blue Loan Services have received a lot of praise for their work with the homeowners of California. For years the company has provided the lowest wholesale mortgage rates and ...
~ Little known facts about how to observe the Federal Holiday from Cricket
Colorado based Air Comm Corporation announced today it has completed the acquisition of Texas based Meggitt , Inc., formerly Keith Products. Air Comm Corporation is the world leader in engineered design and manufacture of Environmental Control ...
Vanda Pharmaceuticals Inc. today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland . Vanda was honored at the TCM's 25 Annual Tech Awards Celebration held in Bethesda, Maryland. The ...
In response to the adoption of the Boy Scouts of America Membership Standards Resolution by the Boy Scouts of America National Council, the BSA - Utah National Parks Council released the following statement:
Rick Barbrick, President and COO of The Briad Restaurant Group, the T.G.I. Friday's franchisee that operates 16 T.G.I. Friday's restaurants in New Jersey, today issued the following statement in response to recent allegations from the New Jersey's ...